Georgia Society of Clinical Oncology Logo

3330 Cumberland Blvd., Suite 200
Atlanta, GA 30339
Phone: 770-951-8427

A New Indication In The 1st Line Treatment Of Advanced NSCLC In Combination With Chemotherapy

Meeting Host

Regeneron & OMedLive

Registration Deadline

no RSVP Date

Description

LIBTAYO® (cemiplimab-rwlc) in combination with platinum-based chemotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is locally advanced where patients are not candidates for surgical resection or definitive chemoradiation OR metastatic.

LIBTAYO as a single agent is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (tumor proportion score [TPS] >e;50%) as determined by an FDA-approved test, with no EGFR, ALK, or ROS1 aberrations, and is locally advanced where patients are not candidates for surgical resection or definitive chemoradiation OR metastatic.

Featured Speakers

  • Dr. Martin Dietrich, MD, PhD - Florida Cancer Specialists & Research Institute
  • Dr. Jason Porter - West Cancer Center
  • Dr. Chaitali Nangia - Hoag Medical Group

When

Date: Tuesday, January 24, 2023
Times: 12:00pm ET, 3:00pm ET, 6:30pm ET

Where

This is a Virtual Meeting.

Meeting Flyer

Meeting details are available on the meeting flyer below.

Registration

Register for Meeting

Related Information

Contact GASCO

Voice: 770-951-1018 Fax: 770-951-2157

Georgia Society of Clinical Oncology
3330 Cumberland Boulevard, Suite 225
Atlanta, GA 30339

gasco logo